The role of the low density lipoprotein receptor (LDLR) in the clearance of apo-B48-containing lipoproteins and the role of the LDLR-related protein (LRP) in the removal of apo-B100-containing lipoproteins have not been clearly defined. To address these issues, we characterized LDLRdeficient mice homozygous for an "apo-B48-only" allele, an "apo-B100-only" allele, or a wild-type apo-B allele ( Ldlr 
Introduction
The B apolipoproteins (apo-B100 and apo-B48) have been studied extensively because they play central roles in lipoprotein assembly, plasma lipid metabolism, and atherogenesis (1, 2) . Apo-B100 is essential for the assembly of very low density lipoproteins (VLDL) 1 in the human liver and is virtually the only protein component of cholesterol-rich low density lipoproteins (LDL) (3) . Apo-B48, a truncated apo-B containing the amino-terminal portion of apo-B100, is required for the assembly of chylomicrons in the intestine (2, 3) . Apo-B48 is synthesized as a result of apo-B mRNA editing, which changes codon 2153 (CAA, specifying Gln) to a translational stop codon (4) . In some mammals, including mice and rats, but not humans, the liver expresses apo-B mRNA editing activity and therefore synthesizes apo-B48 in addition to apo-B100 (5) . In mice, approximately 70% of the hepatic apo-B transcripts code for apo-B48 (6) .
Apo-B100-containing LDL bind to and are taken up by the LDL receptor (LDLR), in both hepatic and extrahepatic tissues. When the LDLR is absent or defective, as in familial hypercholesterolemia, the plasma levels of apo-B100 and LDL cholesterol are markedly elevated (7) . Apo-B48 lacks the portion of the apo-B molecule that interacts with the LDLR and therefore cannot directly mediate the uptake of lipoproteins by the LDLR (8) . However, apo-B48-containing lipoproteins accommodate a large amount of apo-E (9), which is a ligand for both the LDLR and the LDLR-related protein (LRP) (10, 11) . Several recent studies have suggested that the LRP plays a role in the removal of apo-B48-containing lipoproteins from the plasma (12, 13) , but the relative importance of the LRP and the LDLR in the uptake of apo-B48-containing lipoproteins has never been defined precisely.
In this study, we investigated the mechanisms for the uptake of apo-B48-and apo-B100-containing lipoproteins by the LDLR and by the LRP. Specifically, we sought to understand whether the LDLR has a significant role in the clearance of apo-B48-containing lipoproteins from the plasma. We also sought to determine whether the LRP, from the perspective of lipoprotein metabolism, was simply a receptor for the apo-B48-containing lipoproteins, or whether it also has a measurable effect on the metabolism of apo-B100-containing lipoproteins. To address these issues, we have characterized gene-targeted mice that synthesize exclusively apo-B48 ("apo-B48-only" mice) or exclusively apo-B100 ("apo-B100-only" mice), both in the presence and absence of LDLR expression and in the presence and absence of receptor-associated protein (RAP) expression. Our studies have shown that the LDLR does play a significant role in the clearance of apo-B48-containing lipoproteins, but that the LRP also has a major role. Interestingly, the LRP has no apparent role in the metabolism of apo-B100-containing lipoproteins, even when LDLR activity is absent. Thus, from the perspective of lipoprotein metabolism, the LRP is an "apo-B48-containing lipoprotein" receptor. 
Methods

Generation of LDLR
Apob
ϩ / ϩ mice) (14, 16) . The apo-E-deficient mice also had a mixed genetic background ( ‫ف‬ 75% C57BL/6 and 25% 129/sv). All mice were weaned at 21 d, fed a chow diet, and housed in a full-barrier facility with a 12-h light/dark cycle.
Plasma lipid and lipoprotein measurements. Total plasma cholesterol and triglyceride concentrations were measured on fresh plasma samples with colorimetric assays (16) . Total cholesterol and triglyceride levels were measured at 5 mo of age, as well as immediately before and 5 d after intravenous injection of adenoviral preparations. The distribution of lipids within the plasma lipoprotein fractions was assessed by fast phase liquid chromatography (FPLC), using plasma pooled from 5 mice (14) .
Analysis (17) . For these studies, plasma was pooled from 5-10 female mice of each genotype. VLDL diameters were determined by dynamic light scattering (17) and are reported as the mean Ϯ SD (nm). LDL and HDL sizes were assessed by nondenaturing PAGE (17) .
Radioimmunoassays (RIAs) for mouse apo-B100. To measure the concentration of mouse apo-B100 in mouse plasma, we used two solid-phase, mAb-based RIAs. The first was a competitive RIA that measured the ability of the apo-B100 in mouse plasma samples to compete with immobilized mouse LDL for binding to a 125 I-labeled mAb against mouse apo-B100. (Mouse mAbs specific for mouse apo-B100 were generated in Apob 48/48 mice that had been immunized with mouse apo-B100 [C.H. Zlot, L. Flynn, M.M. Véniant, E. Kim, M.
Raabe, S.P.A. McCormick, P. Ambroziak, L.M. McEvoy, and S. Young, manuscript submitted for publication]. All mice are available from Jackson Labs.) Plasma apo-B100 levels in different groups of mice are presented as the percentage of the amount of apo-B100 in wild-type mice. Mouse apo-B100 concentrations were also measured with a direct-binding "sandwich" RIA (18, 19) , using two different mouse apo-B100-specific mAbs.
Analysis of apo-B in the plasma by Western blotting. To compare the amounts of apo-B48 and apo-B100 in different plasma samples and to judge the relative amounts of apo-B48 and apo-B100 in mouse plasma, we performed Western blots of polyacrylamide/SDS gel as previously described (16) . The intensity of the bands was quantified with a GS300 transmittance/reflectance scanning densitometer and the GS-365 data system for densitometer (Hoefer Scientific Instruments, San Francisco, CA).
Large-scale preparation of the recombinant adenovirus. A recombinant adenovirus containing the cDNA for rat receptor-associated protein (Ad-RAP) has been described previously by Willnow and coworkers (12) . As a control, we used an adenovirus containing the cDNA for Escherichia coli ␤ -galactosidase (Ad-␤ -Gal) (20) . Recombinant adenoviruses were prepared on 293 cells as previously described (12) . Plaque-forming units (pfu) were compared to viral particle numbers and were similar for both Ad-RAP and Ad-␤ -Gal (1.1 ϫ 10 12 particles Ϸ 10 10 pfu). Injection of adenoviral preparations into mice. Mice were anesthetized with an intraperitoneal injection of avertin (0.02 mg/g of body weight). Blood samples (50-100 l) were obtained from the retroorbital sinus of each mouse with heparinized collecting tubes. An external jugular vein was exposed, and Ad-␤ -Gal or Ad-RAP (2 ϫ 10 11 particles diluted into 140 l of Tris-buffered saline) was injected intravenously with a 30-gauge needle.
Statistical analysis. Mean lipid levels for each group of mice are reported, along with SEM. Differences in triglyceride levels, cholesterol levels, and apo-B100 levels were modeled by ANOVA with genotype being an intergroup factor. Differences in triglyceride and cholesterol levels measured before and after adenovirus injections were tested with a paired t test.
Results
Plasma lipids and lipoproteins in LDLR-deficient mice.
We measured plasma lipid levels in each group of LDLR-deficient mice (Fig. 1) . LDLR deficiency increased plasma cholesterol levels significantly, regardless of Apob genotype. However, the magnitude of this effect was greatest in the setting of the Apob 100 allele. The plasma cholesterol levels were lower in 
Apob
ϩ/ϩ mice were much higher than in any of the groups of LDLR-deficient mice (Fig. 1) . However, the total plasma cholesterol levels were nearly identical in the Apoe Ϫ/Ϫ Apob 100/100 and Ldlr
Apob 100/100 mice ‫ف(‬ 230Ϯ15 mg/dl). To assess the distribution of lipids within the plasma lipoproteins, we fractionated the plasma on an FPLC column ( mice was virtually identical to that in Apob 100/100 mice, which had normal LDLR activity. However, it is important to note that both the total plasma cholesterol levels ( Fig. 1 ) and the height of the LDL cholesterol peak (Fig. 2 A) Apob ϩ/ϩ mice, as in human apo-B transgenic mice (6, 21, 22) , a large fraction of the triglycerides was contained in the LDL fraction (Fig. 2 B) .
None of the LDLR-deficient mice had large amounts of cholesterol or triglycerides in the VLDL fraction. Indeed, the VLDL cholesterol and triglyceride peaks in the LDLR-deficient mice did not differ significantly from those in mice that had normal levels of LDLR expression (Fig. 2) Apo-B levels in apo-E-and LDLR-deficient mice. To quantify the amount of apo-B100 in the plasma, we used mAbbased RIAs (Fig. 3 A) as well as Western blot analysis (Fig. 3  B) . Relative levels of apo-B48 in different mouse plasma samples were assessed by Western blots. Relative to Apob ϩ/ϩ mice, the plasma apo-B100 levels in Ldlr
Apob 100/100 mice were increased by five-and eightfold, respectively (Fig. 3 A) . LDLR deficiency resulted in a significant increase in the plasma levels of apo-B48, although the increase was much smaller than that caused by apo-E deficiency (Fig. 3 B) . Densitometric analysis of Western blots revealed that the plasma apo-B48 levels in Ldlr Apob 100/100 than in Apob 100/100 mice. (Why apo-E deficiency produces a sharp ‫ف(‬ 65%) decrease in mouse apo-B100 levels in the setting of the Apob ϩ allele but an increase ‫ف(‬ 165%) in apo-B100 levels in the setting of the Apob 100 allele is not clear. We speculate that this difference may relate to the fact that the apo-B100 is produced by both the intestine and liver in the setting of the Apob 100 allele but apo-B100 is produced only by the liver in the setting of the Apob ϩ allele. In the setting of apo-E deficiency, it is possible that intestinal apo-B100-containing lipoproteins are cleared somewhat less efficiently by the LDLR than apo-B100-containing lipoproteins derived from the liver.)
Metabolic effects of adenoviral-mediated overexpression of RAP in the liver. To assess the effect of the LRP on the metabolism of apo-B100-containing lipoproteins, we blocked hepatic LRP function in LDLR-deficient mice (both in Ldlr
Apob 100/100 mice) and then determined whether the plasma apo-B100 levels were perturbed. To block LRP function, we used a recombinant adenovirus to overexpress RAP in the liver. We also defined the impact of RAP overexpression on plasma apo-B48 levels in both Ldlr To assess the impact of RAP overexpression on apo-B metabolism, we measured plasma apo-B levels in Ldlr
, and Ldlr
Apob 100/100 mice before and 5 d after the injection of the adenoviral preparations. Of note, overexpression of RAP had no effect on plasma apo-B100 levels in Ldlr
Apob 100/100 mice, as assessed by a mAb-based RIA (Fig. 4 A) or by Western blot analysis (Fig. 4 B) . These results in LDLR-deficient mice strongly suggest that blocking LRP function has little or no effect on the uptake and clearance of apo-B100-containing lipoproteins. The absence of a measurable effect of RAP overexpression on plasma apo-B100 levels stands in contrast to the effects on plasma apo-B48 levels. In both Ldlr Apob 48/48 mice, RAP overexpression caused a four-to fivefold increase in plasma apo-B48 levels (Fig. 4 B) .
The plasma lipids and the distribution of lipids within the lipoprotein fractions were also assessed 5 d after the injection of Ad-␤-Gal and Ad-RAP. Plasma lipid levels increased after the injection of both of the adenoviruses, although Ad-RAP had a much greater effect (Fig. 5, A and B) . After the injection of Ad-␤-Gal, the plasma cholesterol and triglyceride levels increased by ‫ف‬ 30% and ‫ف‬ 100%, respectively, and the magnitude of the changes was similar in Ldlr (Fig. 5 B) . 
100/100 mice. Thus, relative to the number of apo-B-containing lipoproteins in the plasma (see Fig. 4 
100/100 mice in the absence of any effect on plasma apo-B100 levels strongly suggested that RAP had the effect of increasing lipoprotein particle size. To gauge the size of lipoproteins in the plasma, we used FPLC fractionation studies to assess the distribution of lipids in the plasma 
100/100 mice after Ad-RAP injection (Fig. 6, C and D; compare with the baseline distribution of lipids in Fig. 2) . After the injection of Ad-␤-Gal, there were increased lipids in the VLDL fraction (Fig. 6, A and B) , although the magnitude of this effect was less than that observed after Ad-RAP.
In addition to the FPLC fractionation studies, we also assessed VLDL particle diameter in Ldlr Table I ). Thus, the percentage increase in VLDL diameter with Ad-RAP was similar for apo-B48-and apo-B100-containing lipoproteins.
Apo-B48 and apo-B100 levels after expression of RAP in wild-type and Apob
48/48 mice. In addition to assessing the effects of RAP in LDLR-deficient mice, we determined its effect on apo-B100 and apo-B48 levels in wild-type mice (Fig. 7) . In those mice, we suspected that RAP overexpression would result in increased plasma apo-B100 levels, since high levels of RAP expression interfere with the binding of lipoproteins to the LDLR, at least to a small extent (23, 24) . This suspicion was confirmed. In wild-type mice, RAP overexpression increased plasma apo-B100 levels twofold (Fig. 7) . The effects of RAP overexpression on the apo-B48 levels in wild-type mice were more intriguing because they shed light on the issue of whether the clearance of apo-B48-containing lipoproteins normally depends largely or entirely on the LDLR or depends on both the LDLR and the LRP. If the clearance of apo-B48-containing lipoproteins in wild-type mice were entirely or largely due to the LDLR, one would expect to observe an ‫ف‬ twofold elevation in plasma apo-B48 levels, similar in magnitude to the increase in plasma apo-B100 levels. This was not the case; RAP overexpression in wild-type mice increased apo-B48 levels sixfold. Finding a much greater increase in plasma apo-B48 levels strongly suggests that the LRP has a substantial role in the clearance of apo-B48-containing lipoproteins, even in the setting of normal levels of LDLR expression. Consistent with these results, we observed a sevenfold increase in plasma apo-B48 levels in Apob 48/48 mice after the injection of Ad-RAP.
Discussion
The role of the LDLR in removing apo-B100-containing lipoproteins from the plasma is well established (25) , and recent studies have implicated the LRP in the clearance of apo-B48-containing lipoproteins in animals that are deficient in the LDL receptor (12, 13, 26) . In the current study, we sought to define whether the LRP can play a role in removing apo-B100-containing lipoproteins from the plasma and whether the LDLR has a significant role in the clearance of apo-B48-containing lipoproteins. To examine these issues, we used adenoviral-mediated overexpression of RAP to block LRP function in LDLR-deficient mice that synthesized exclusively apo-B48 or apo-B100. The use of "apo-B48-only" and "apo- 
Apob
48/48 mice, apo-B48 levels were 1133Ϯ222 AU before and 5455Ϯ693 AU after injection.
Downloaded from http://www.jci.org on April 6, 2017. https://doi.org/10.1172/JCI4164 B100-only" mice allowed us to examine lipoprotein metabolism in a less complex setting, one where the normal competition between apo-B48-and apo-B100-containing lipoproteins for metabolic processing and uptake (27) is nonexistent. Our experiments described here have clarified the roles of both the LRP and the LDLR by showing that the LRP has little if any capacity to remove apo-B100-containing lipoproteins from the plasma and that the LDLR plays a significant role in the clearance of apo-B48-containing lipoproteins.
If the LRP played a significant role in removing apo-B100-containing lipoproteins from the plasma, we reasoned that blocking LRP function with RAP would cause significantly increased plasma levels of the apo-B100-containing lipoproteins. Our experiments demonstrated that this did not occur. As judged by Western blots as well as mAb-based RIAs, RAP overexpression did not affect the plasma levels of apo-B100 in Ldlr Apob ϩ/ϩ mice. The striking effects on plasma apo-B48 levels, along with the absence of an effect on apo-B100 levels, indicate that the LRP is, from the perspective of lipoprotein metabolism, a receptor only for the apo-B48-containing lipoproteins.
The uptake of apo-B-containing remnant lipoproteins by the LRP is mediated by apo-E (28). Interestingly, the amount of apo-E on circulating remnant lipoproteins may be insufficient for uptake by the LRP; rather, these lipoproteins appear to require a "supplemental dose" of apo-E before uptake occurs (29) . The laboratory of Linton and Fazio reported data suggesting that the apo-E "supplement" must be provided by hepatocytes (30) . They found that apo-E-rich remnant lipoproteins were readily taken up (as a result of the LRP) by hepatocytes that were deficient in the LDLR but not by hepatocytes that lacked both the LDLR and apo-E. These experiments suggested that the uptake of apo-E-containing remnant lipoproteins by the LRP is largely or completely dependent on the ability of hepatocytes to synthesize and secrete apo-E (30) . These data led to an intriguing hypothesis: that the apo-E se- creted by hepatocytes initially binds to the LRP, and the bound apo-E subsequently attaches to remnant lipoproteins. Remnant lipoproteins supplemented with apo-E in this fashion would then be internalized by the LRP. Alternatively, the apo-E secreted by hepatocytes into the space of Disse may be captured by proteoglycans and then facilitate the LRP-mediated uptake of lipoproteins (31) . However, regardless of how "apo-E supplementation" occurs, our data indicate that the LRP is active only in the uptake of apo-B48-containing lipoproteins. We suggest that the presence of the carboxyl terminus of apo-B100 (amino acids 2153-4536) on the surface of the lipoprotein prevents the lipoprotein particle from binding a sufficient dose of "supplemental" apo-E, thereby preventing its uptake via the LRP.
The studies of Willnow et al. (12), Ishibashi et al. (11, 32) , and Rohlmann et al. (13) highlighted the role of the LRP in the uptake of apo-B48-containing lipoproteins in LDLR-deficient mice. However, the issue of whether the LDLR plays a significant role in the uptake of apo-B48-containing lipoproteins has never been addressed definitively in in vivo models. Our studies with Ldlr 
48/48 mice did not have severe hypercholesterolemia, but they had two-to threefold higher plasma apo-B48 levels, higher total cholesterol levels, and much higher LDL cholesterol levels than the Apob 48/48 mice. These observations indicate that the LDLR normally plays a significant role in the clearance of apo-B48-containing lipoproteins.
The fact that the LDLR has an easily detectable role in the clearance of apo-B48-containing lipoproteins raises the question of whether the LDLR, under normal circumstances, clears most or all of the apo-B48-containing lipoproteins from the plasma. Our data would argue that it does not; rather, we believe that the LRP has a key role in the clearance of apo-B48-containing lipoproteins, even with physiologically normal levels of LDLR expression. First, in the setting of homozygosity for the Apob 48 allele, we documented that apo-E deficiency caused a far greater increase in plasma apo-B48 levels than LDLR deficiency, suggesting that a significant fraction of Western blot analysis of plasma apo-B levels in wild-type and Apob 48/48 mice, both before and after injection of Ad-RAP. In wild-type mice, apo-B100 levels increased approximately twofold after injection of Ad-RAP (5414Ϯ938 AU before and 12765Ϯ2062 AU after injection). In wild-type mice, apo-B48 levels increased sixfold after injection of Ad-RAP (2752Ϯ1749 AU before and 16994Ϯ3029 AU, after injection); in Apob 48/48 mice, apo-B48 levels increased sevenfold after injection of Ad-RAP (2601Ϯ587 AU before and 19295Ϯ6500 AU, after injection).
apo-B48-lipoproteins is cleared from the plasma via a second receptor that recognizes apo-E (i.e., the LRP). Second, in wildtype mice, adenoviral-mediated overexpression of RAP produced a far greater increase in apo-B48 levels than in apo-B100 levels. Both observations strongly suggest that the LRP plays a fundamental role in the clearance of apo-B48-containing lipoproteins, even with normal LDLR expression, and that it is not simply a "back-up" for the LDLR. A primary role for the LRP in lipoprotein uptake is also supported by the recent studies of Rohlmann et al. (13) . They inactivated the LRP gene in the liver and documented a twofold increase in hepatic LDLR expression. That observation suggests that the LRP is normally involved in lipoprotein uptake and that eliminating LRP-mediated uptake results in an upregulation of LDLR expression.
Our measurements of VLDL size provided intriguing insights into the metabolism of apo-B48 and apo-B100. 
100/100 mice is due to absent LDLR uptake and virtually nonexistent LRP uptake, leading to more complete removal of core lipids. To our knowledge, these data are the first to raise the possibility that the efficiency of receptor-mediated uptake could have striking influences on the size of circulating VLDL.
In the prior studies by Willnow and coworkers (12) and in our current studies, adenoviral expression of RAP in the setting of LDLR deficiency resulted in turbid plasma and grossly elevated plasma cholesterol and triglyceride levels. The hyperlipidemia observed after Ad-RAP injection was much more severe than that in mice lacking LRP gene expression in the liver (13) . Our experiments indicate that the Ad-RAP hyperlipidemia can be resolved into two components. In the case of Ldlr mice developed hypercholesterolemia and hypertriglyceridemia without an increase in apo-B100 levels. The second component leads to the appearance of larger and more buoyant lipoproteins in the plasma, perhaps as a result of altered lipolytic processing of lipoproteins. At least in part, the larger lipoproteins could relate to the viral infection itself. In our experiments, and in those of Tsukamoto (33) , the injection of Ad-␤-Gal led to a shift toward larger lipoproteins (more VLDL on the FPLC fractionation studies), although the magnitude of this effect was less than that observed with Ad-RAP.
In their original description of the LDLR knockout mice, Ishibashi et al. (15) noted that the hypercholesterolemia was only mild to moderate, in contrast to the severe hypercholesterolemia that occurs in LDLR-deficient humans. They reasoned that the mild phenotype in the mouse probably relates to the ability of mice to synthesize apo-B48-containing lipoproteins in the liver. In our studies, we have demonstrated that their reasoning was correct: the Ldlr 
ϩ/ϩ mice prevents them from developing significant atherosclerosis when fed a low-fat, chow diet (34). Although we have not yet performed systematic studies of atherosclerosis in the three groups of LDLRdeficient mice described in this paper, we have noted very severe atherosclerosis throughout the arterial tree in a few Ldlr Ϫ/Ϫ Apob 100/100 mice that were maintained on a low-fat chow diet for 10 mo (M. Véniant and S. Young, unpublished observations). Moreover, we have noted severe atherosclerosis in a large number of chow-fed Ldlr Ϫ/Ϫ
Apobec1
Ϫ/Ϫ mice, which also synthesize exclusively apo-B100 (35) . We suspect that the Ldlr Ϫ/Ϫ Apob 100/100 and Ldlr Ϫ/Ϫ Apobec1 Ϫ/Ϫ mice will be very attractive as experimental models for atherosclerosis studies. Like most humans with atherosclerosis, these animals have high plasma levels of apo-B100-containing, cholesterolrich LDL.
